3. Reagents for Diabetes Research

3-d) Diabetes Complication

Description Wako Cat. # (Pkg. Size) Note
Aldose Reductase, Human, recombinant 012-23761 (0.4 units) Research for Diabetes Complication-Aldose Reductase Inhibitor
Epalrestat 058-07701 (1 g)
054-07703 (5 g)
D-3-Hydroxybutyrate Dehydrogenase,
from Pseudomonas sp.
086-05441 (5 mg) Used for measurement of D-3-Hydroxy butyric acid and acetoacetic acid in serum, which is ketoic metabolic index on diabetes
Sorbitol Dehydrogenase 199-12391 (500 units) Research for Diabetes Complication

3-e) Glucagon Like Peptides

Exendin-related Peptides

While GLP-1 (Glucagon-like peptide-1), which inhibits glucagon secretion and has insulinotropic action, etc., is expected as a therapeutic agent for treating Type 2 diabetes, it is easy to degrade by intestinal enzymes. Exendin-4 has action comparable to GLP-1 and is resistant to degrade.

Description [Peptide Institute No.] Wako Cat. # (Pkg. Size) Note
Exendin-4 050-07261 (0.5 mg) Strong antagonist of GLP-1 Receptor, Keep at -20°C
Exendin-3 053-07251 (0.5 mg) Stable GLP-1 analog, Keep at -20°C
Exendin-(9-39) 056-07241 (0.5 mg) Antagonist of GLP-1 Receptor/Competitive inhibitor of Exendin-3, Exendin-4, Keep at -20°C
Exendin-4 (3-39) 057-07271 (0.5 mg) Strong antagonist of GLP-1 Receptor, Keep at -20°C
Exendin (5-39) [4345-v] 330-43451 (0.5 mg) GLP-1 Receptor Antagonist, Keep at -20°C
(Des-His1, Glu8)-Exendin-4 054-07281 (0.5 mg) GLP-1 Receptor Antagonist, Keep at -20°C
Glucagon (Human) [4098-s] 339-40981 (0.1 mg) Keep at -20°C
Glucagon-like Peptide 1 (Human, 7-36 Amide) [4344-v] 333-43441 (0.5 mg) Inhibitor for Food Intake, Keep at -20°C
Glucagon-like Peptide 1 (Human, 7-37) [4280-v] 335-42801 (0.5 mg) GLP-1, Keep at -20°C
Glucagon-like Peptide 2 (Human) [4376-v] 335-43761 (0.5 mg) GLP-2, Keep at -20°C

[ ]: Peptide Institute Product No.

3-f) Resistance to insulin

Resistin, recombinant [ Resistin : molecule termed as "Resistin" signifying resistance to insulin ]

Resistin is a dimeric hormone secreted by mast cells and is attracting attention as a substance which impairs insulin action. TNF-a and free fatty acid are known as resistins.
Serum resistin concentration decreases with administration of antidiabetic drugs and is elevated when obesity occurs. It was also found that administration of resistin-neutralizing substance to obese mice restored serum glucose levels and insulin action. Based on these fi ndings, it is believed that resistin is a key link between obesity and diabetes.

Human Resistin
Description : Lyophilized from 10 mmol/L sodium citrate (pH 3.0). Filtered and sterilized.
Human resistinMouse Resistin
AppearanceLyophilized from the fi lter sterilized 10 mol/L sodium citrate (pH 3.0)Lyophilized from the fi lter sterilized 20 mmol/L Tris (pH 8.0)
SourceHuman resistin cDNA expressed in E. coli.Source : Mouse resistin cDNA expressed in E. coli.
Molecular Weight19,50020,200
Endotoxins< 0.1 ng/μg (1 EU/μg)< 0.1 ng/μg (1 EU/μg)

Steppan, C.M., et al.: "The hormone resistin links obesity to diabetes", Nature, 409, 307-12 (2001).
Description Wako Cat. # (Pkg. Size) Note
Resistin, Human (Lyophilized) 187-01801 (25 μg) Keep at -20°C
Resistin, Mouse (Lyophilized) 184-01811 (25 μg)
page top
Wako Product Update Bio-No.2 [ page. 19 ]